Trusted Resource for Clinical Trials, Protocols & Progress
Rare disease clinical trials often span multiple countries and rely on diverse laboratories for sample testing, biomarker analysis, and endpoint validation. Without standardized laboratory procedures, variability in data can compromise trial integrity, delay regulatory approvals, and undermine the scientific value of findings.
Click to read the full article.
Clinical supply logistics are a critical yet often underappreciated component of clinical trial execution. In ultra-rare disease trials, this complexity is magnified by limited availability of the investigational product (IP), small and geographically dispersed patient populations, highly specialized storage conditions, and strict regulatory import/export requirements.
Click to read the full article.
Contract negotiation is a foundational component of clinical trial startup. In global rare disease studies, the negotiation process is uniquely complex due to limited site experience, small budgets, multinational regulations, and urgent timelines. These trials often involve sponsors with limited commercial infrastructure and rely heavily on academic institutions, hospitals, or rare disease centers of excellence—which may not have streamlined contracting practices.
Click to read the full article.
Rare disease clinical trials often rely on a small number of specialized sites and highly experienced principal investigators (PIs). In many cases, a single PI may serve as the only qualified clinician with in-depth knowledge of the disease, investigational product, and protocol-specific assessments at their site.
Click to read the full article.
Rare disease clinical trials typically involve small cohorts—sometimes fewer than 20 patients—making every datapoint crucial. These studies often require complex data collection tools to capture nuanced, protocol-specific endpoints such as functional scores, genetic markers, or patient-reported outcomes (PROs).
Click to read the full article.
Rare disease clinical trials often require a multi-national approach due to the geographically dispersed nature of eligible patients. Enrolling adequate participants from a single region is rarely feasible, necessitating coordination across multiple countries, each with its own regulatory, cultural, and operational landscape.
Click to read the full article.
Rare disease trials face unique challenges that make traditional, intensive on-site monitoring inefficient and often unsustainable. Small patient populations, dispersed across numerous global sites, mean fewer patients per site and higher operational costs. Moreover, these studies often involve complex endpoints, novel therapies, and high protocol sensitivity—all demanding focused oversight.
Click to read the full article.
Long-term biological sample storage is an essential component of rare disease clinical trials. Due to the small number of patients and the progressive nature of many rare diseases, biospecimens often represent irreplaceable data sources. Properly stored samples may be reanalyzed years later for biomarker discovery, regulatory re-submissions, or personalized medicine approaches.
Click to read the full article.
Supply chain disruptions in clinical trials can jeopardize not only timelines but also patient safety—particularly in rare disease studies where patient populations are small and geographically dispersed. Unlike large trials where inventory buffers may absorb supply shocks, rare disease trials must carefully balance limited investigational product (IP), biological samples, and comparator drugs across global sites. Any delay, stockout, or temperature excursion could compromise the entire study or force protocol amendments.
Click to read the full article.
In ultra-rare disease clinical trials, where eligible patient populations may be limited to only a few individuals per country—or even globally—site feasibility takes on an elevated level of importance. A misstep in site selection can lead to zero enrollment, delays, protocol amendments, or even trial failure. Sponsors cannot afford traditional high-volume approaches or selection based on historical metrics alone.
Click to read the full article.
